Screening of diagnostic markers for osteosarcoma

Wu,Dajiang; Chen,Kai; Bai,Yushu; Zhu,Xiaodong; Chen,Ziqiang; Wang,Chuanfeng; Zhao,Yingchuan; Li,Ming

doi:10.3892/mmr.2014.2546

Screening of diagnostic markers for osteosarcoma

Authors:
- Dajiang Wu
- Kai Chen
- Yushu Bai
- Xiaodong Zhu
- Ziqiang Chen
- Chuanfeng Wang
- Yingchuan Zhao
- Ming Li
View Affiliations

Affiliations: Department of Orthopedics, Changhai Hospital, Shanghai 200433, P.R. China
Published online on: September 8, 2014 https://doi.org/10.3892/mmr.2014.2546
Pages: 2415-2420

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma, which is the most common type of highly malignant bone tumor in children and adolescents, has poor diagnosis and 2-year survival rates of 15-20% following surgery or radiotherapy, and has therefore generated marked attention. In order to investigate the potential biomarkers for diagnosing osteosarcoma, the expression profiling data from normal and disease tissues were compared, respectively, and the differentially‑expressed genes were analyzed by three different statistical tests. Interacting proteins were determined and an interaction network was constructed by Search Tool for the Retrieval of Interacting Genes database. Subsequently, the protein interaction network was decomposed and Gene Otology annotation using Cytoscape, Mcode and Bingo, was conducted on the function modules. Finally, three differentially‑expressed genes GJA1, COL1A2 and COL5A2 were identified, and an interaction network was successfully generated with COL1A2 and COL5A2 at the core. From the results, it was observed that COL1A2 and COL5A2 interact with a number of genes of the matrix metalloprotease (MMP) family, including MMP1, MMP2, MMP3 and MMP14, TGFβ and RUNX2. Furthermore, these genes have been confirmed to be important in the tumorigenesis of osteosarcoma. It was hypothesized that the upregulation of the COL gene family may be considered as a diagnostic marker for osteosarcoma and collagen may be administered as a therapy.

View Figures

View References

1	Fletcher CD, Unni KK and Mertens F; WHO; IARC. WHO classification of tumours: Pathology and genetics of tumours of soft tissue and bone. 4th edition. IARC Press; Lyon, France: 2002
2	Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
3	Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–8852. 2005. View Article : Google Scholar
4	Abramson DH, Ellsworth RM, Kitchin FD and Tung G: Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 91:1351–1355. 1984. View Article : Google Scholar : PubMed/NCBI
5	Kitchin FD and Ellsworth RM: Pleiotropic effects of the gene for retinoblastoma. J Med Genet. 11:244–246. 1974. View Article : Google Scholar : PubMed/NCBI
6	Ladanyi M and Gorlick R: Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr Pathol Mol Med. 19:391–413. 2000. View Article : Google Scholar
7	Hung J and Anderson R: p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl. 273:68–73. 1997.PubMed/NCBI
8	Miller CW, Aslo A, Won A, Tan M, Lampkin B and Koefflar HP: Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol. 122:559–565. 1996. View Article : Google Scholar : PubMed/NCBI
9	Noble-Topham SE, Burrow SR, Kandel RA, et al: SAS is amplified predominantly in surface osteosarcoma. J Orthop Res. 14:700–705. 1996. View Article : Google Scholar : PubMed/NCBI
10	Paoloni M, Davis S, Lana S, et al: Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics. 10:6252009. View Article : Google Scholar : PubMed/NCBI
11	Fujita A, Sato JR, de Rodrigues LO, Ferreira CE and Sogayar MC: Evaluating different methods of microarray data normalization. BMC Bioinformatics. 7:4692006. View Article : Google Scholar : PubMed/NCBI
12	Troyanskaya O, Cantor M, Sherlock G, et al: Missing value estimation methods for DNA microarrays. Bioinformatics. 17:520–525. 2001. View Article : Google Scholar : PubMed/NCBI
13	Pollard KS, Dudoit S and van der Laan MJ: Multiple testing procedures: R multtest package and applications to genomics. Bioinformatics and Computaional Biology Solutions using R and Bioconductor. Statistics for Biology and Health 2005. 249–271. 2005.
14	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc. B. 289–300. 1995.
15	Szklarczyk D, Franceschini A, Kuhn M, et al: The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39:D561–D568. 2011. View Article : Google Scholar
16	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rivera CG, Vakil R and Bader JS: NeMo: network module identification in Cytoscape. BMC Bioinformatics. 11:S612010. View Article : Google Scholar : PubMed/NCBI
18	Maere S, Heymans K and Kuiper M: BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 21:3448–3449. 2005. View Article : Google Scholar
19	Olsen BR: Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias. Bone. 17:S45–S49. 1995. View Article : Google Scholar
20	Prockop DJ and Kivirikko KI: Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem. 64:403–434. 1995. View Article : Google Scholar : PubMed/NCBI
21	Vikkula M, Metsäranta M and Ala-Kokko L: Type II collagen mutations in rare and common cartilage diseases. Ann Med. 26:107–114. 1994. View Article : Google Scholar : PubMed/NCBI
22	Ghosh AK: Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med. 227:301–314. 2002.PubMed/NCBI
23	Branton MH and Kopp JB: TGF-β and fibrosis. Microbes Infect. 1:1349–1365. 1999.
24	Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor β in human disease. N Engl J Med. 342:1350–1358. 2000.
25	Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M and Varga J: Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J Invest Dermatol. 112:49–57. 1999.
26	Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73:161–195. 1993.PubMed/NCBI
27	Holmbeck K, Bianco P, Caterina J, et al: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 99:81–92. 1999. View Article : Google Scholar
28	Makareeva E, Han S, Vera JC, et al: Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res. 70:4366–4374. 2010. View Article : Google Scholar
29	Yong HY and Moon A: Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 30:75–81. 2007. View Article : Google Scholar : PubMed/NCBI
30	Chen PN, Kuo WH, Chiang CL, et al: Black rice anthocyanins inhibit cancer cells invasion via repressions of MMPs and u-PA expression. Chem Biol Interact. 163:218–229. 2006. View Article : Google Scholar : PubMed/NCBI
31	Itoh Y and Seiki M: MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol. 206:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
32	Nabha SM, dos Santos EB, Yamamoto HA, et al: Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer. 122:2482–2490. 2008. View Article : Google Scholar : PubMed/NCBI
33	Mori K, Enokida H, Kagara I, et al: CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int J Oncol. 34:1593–1602. 2009.PubMed/NCBI
34	Pratap J, Galindo M, Zaidi SK, et al: Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 63:5357–5362. 2003.PubMed/NCBI
35	Thomas DM, et al: Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biology. 167:925–934. 2004. View Article : Google Scholar : PubMed/NCBI
36	Thomas DM, Carty SA, Piscopo DM, et al: The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 8:303–316. 2001. View Article : Google Scholar : PubMed/NCBI
37	Jeon DG, Lee SY and Kim JW: Bone primary sarcomas undergone unplanned intralesional procedures-the possibility of limb salvage and their oncologic results. J Surg Oncol. 94:592–598. 2006. View Article : Google Scholar
38	Ayerza MA, Muscolo DL, Aponte-Tinao LA and Farfalli G: Effect of erroneous surgical procedures on recurrence and survival rates for patients with osteosarcoma. Clin Orthop Relat Res. 452:231–235. 2006. View Article : Google Scholar : PubMed/NCBI
39	Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP and Grimer RJ: Pre-and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer. 41:2846–2852. 2005. View Article : Google Scholar : PubMed/NCBI